The increasing demand for accessible and convenient mental healthcare services is a major driver in the chatbots for the mental health and therapy market. Traditional mental healthcare services often face barriers that hinder individuals from accessing timely support when they need it most. Chatbots address these barriers by providing immediate access to mental health support. They can be accessed through various digital platforms, including smartphones and web-based applications, allowing users to engage in conversations from the comfort and privacy of their own homes. This convenience and accessibility make chatbots attractive for individuals seeking mental health support.
The chatbots for mental health and therapy market size is forecasted to expand from USD 1.77 billion in 2025 to USD 10.16 billion by 2034, growing at a CAGR of 21.3% from 2025 to 2034, as a result of rising demand for accessible and convenient healthcare services. This growth reflects the increasing reliance on digital solutions to address mental health challenges and bridge gaps in traditional care models.
Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5068
Due to the rise in the demand for mental health services, there is increased investment in the development of advanced chatbots for mental health and therapy. For instance, in March 2021, Wysa Ltd, a mental health app company, closed a Series A funding round of $5.5 million run by Boston’s W Health Ventures, the Google Assistant Investment Program, pi Ventures, and Kae Capital. In addition, the company raised around $20 million in a Series B funding round to expand its business capacity in July 2022. This surge in investment underscores the growing recognition of the role chatbots can play in mental healthcare.
The increasing prevalence of mental health disorders significantly increases the adoption of chatbots for mental health and therapy. According to the WHO 2020 estimates, depression is the leading cause of disability in the world, and around 264 million people across the globe suffered from depression in 2020. The COVID-19 pandemic further exacerbated the mental health crisis. According to a Lancet publication, the pandemic triggered 76 million cases of anxiety and 53 million cases of depression worldwide. This alarming rise in mental health conditions highlights the urgent need for accessible mental health support solutions like chatbots.
Moreover, the use of chatbots can help overcome the stigma associated with mental health. Some individuals may feel uncomfortable or hesitant to seek help from traditional mental healthcare providers due to perceived judgment or discrimination. Chatbots offer a non-judgmental and confidential space for individuals to express their concerns and receive support without fear of stigma. By providing a safe and private platform, chatbots encourage more people to seek help and manage their mental well-being effectively.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/chatbots-for-mental-health-and-therapy-market
Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5068
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The global digital health market is witnessing a steady rise and much of it is driven by the increasing number… Read More
In 2025, North America emerged as the clear frontrunner in the healthcare Contract Research Organization (CRO) market and it’s easy… Read More
Powering the Future of Cell and Gene Therapy Virocell Biologics, a leading name in vector manufacturing for cell and gene… Read More
A Big Leap Forward in PAH Care Pahr Therapeutics Inc. has raised $14 million in seed funding to accelerate its… Read More
Reimagining Immunology, Together In a groundbreaking partnership, Bristol Myers Squibb (BMS) and Bain Capital have come together to launch a… Read More
Genethon, a global leader in gene therapy for rare genetic diseases, has received the green light from the UK and… Read More